The approval gives Inovio its first commercial product and pressures rival Precigen, whose shares fell 27% after hours on the news.

An oral alternative to injectable PCSK9 drugs could broaden the cholesterol-lowering class beyond patients who accept shots.

Dupixent royalties and Eylea HD sales drove the beat, reinforcing Regeneron's reliance on partnered immunology revenue.

Lilly's guidance lift underscores how obesity and diabetes franchises are still outrunning pricing pressure.

Hanmi's first homegrown GLP-1 enters a roughly 2 trillion won Korean obesity market at a steep discount to Wegovy and Mounjaro.

India's drug price regulator is tightening compliance as experts push for compulsory licensing to curb oncology markups.

Large-cap pharma earnings show pricing pressure has not yet dented revenue growth.

A manufacturing halt at one Indian plant adds regulatory risk to Sun Pharma's ophthalmology supply.

The fight over Part B payment models could reshape how physician-administered drugs are reimbursed.

Skyrizi and Rinvoq are offsetting Humira erosion, but pipeline questions are mounting.

The approval gives NRx a niche formulation and a near-term commercial catalyst in the psychedelic-adjacent space.

Regulators and compounders are still sorting out rules as obesity drug supply recovers.

Retail traders pushed SLS up 15% on survival data and anticipation of a pivotal trial readout.

The provincial expansion broadens commercial reach for GRAIL's blood-based cancer screening test.

Investors are reassessing Novo's competitive position after fresh obesity data.

Multiple near-term catalysts make Zenas a closely watched immunology name.

Positive Phase 3 results keep Vera on track for a filing in IgA nephropathy.

A win in Sjogren's would diversify Amgen beyond its legacy inflammation portfolio.